Bronstein, Gewirtz & Grossman, LLC is investigating potential legal claims for Sellas Life Sciences investors.
The probe follows an August 28, 2026, report regarding the Phase 3 REGAL trial for cancer therapy Galinpepimut-S (GPS). The clinical trial reached its pre-specified trigger of 80 patient deaths required for final data analysis.
Sellas failed to disclose the results following this milestone. Company shares fell 13.15% on August 28. The stock closed at $13.21 as investors reacted to the lack of communication. This investigation adds to uncertainty surrounding the outcome for the acute myeloid leukemia (AML) treatment.